BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24729456)

  • 1. Fluorine-containing 6,7-dialkoxybiaryl-based inhibitors for phosphodiesterase 10 A: synthesis and in vitro evaluation of inhibitory potency, selectivity, and metabolism.
    Schwan G; Barbar Asskar G; Höfgen N; Kubicova L; Funke U; Egerland U; Zahn M; Nieber K; Scheunemann M; Sträter N; Brust P; Briel D
    ChemMedChem; 2014 Jul; 9(7):1476-87. PubMed ID: 24729456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
    Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
    Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
    J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
    Kulkarni SS; Patel MR; Talele TT
    Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.
    Asproni B; Murineddu G; Pau A; Pinna GA; Langgård M; Christoffersen CT; Nielsen J; Kehler J
    Bioorg Med Chem; 2011 Jan; 19(1):642-9. PubMed ID: 21087867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
    Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis.
    Wu Q; Gao Q; Guo H; Li D; Wang J; Gao W; Han C; Li Y; Yang L
    Mol Biosyst; 2013 Mar; 9(3):386-97. PubMed ID: 23354020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.
    Yoshikawa M; Kamisaki H; Kunitomo J; Oki H; Kokubo H; Suzuki A; Ikemoto T; Nakashima K; Kamiguchi N; Harada A; Kimura H; Taniguchi T
    Bioorg Med Chem; 2015 Nov; 23(22):7138-49. PubMed ID: 26494583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
    Kadoh Y; Miyoshi H; Matsumura T; Tanaka Y; Hongu M; Kimura M; Takedomi K; Omori K; Kotera J; Sasaki T; Kobayashi T; Taniguchi H; Watanabe Y; Kojima K; Sakamoto T; Himiyama T; Kawanishi E
    Chem Pharm Bull (Tokyo); 2018; 66(3):243-250. PubMed ID: 29491258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, SAR study, and biological evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors with reduced CYP3A4 inhibition.
    Hamaguchi W; Masuda N; Miyamoto S; Shiina Y; Kikuchi S; Mihara T; Moriguchi H; Fushiki H; Murakami Y; Amano Y; Honbou K; Hattori K
    Bioorg Med Chem; 2015 Jan; 23(2):297-313. PubMed ID: 25515954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate.
    Li J; Zhang X; Jin H; Fan J; Flores H; Perlmutter JS; Tu Z
    J Med Chem; 2015 Nov; 58(21):8584-600. PubMed ID: 26430878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.
    Harada A; Suzuki K; Miura S; Hasui T; Kamiguchi N; Ishii T; Taniguchi T; Kuroita T; Takano A; Stepanov V; Halldin C; Kimura H
    Nucl Med Biol; 2015 Feb; 42(2):146-54. PubMed ID: 25451212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors.
    Hu E; Kunz RK; Rumfelt S; Chen N; Bürli R; Li C; Andrews KL; Zhang J; Chmait S; Kogan J; Lindstrom M; Hitchcock SA; Treanor J
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2262-5. PubMed ID: 22365755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.
    Meegalla SK; Huang H; Illig CR; Parks DJ; Chen J; Lee YK; Wilson KJ; Patel SK; Cheung WS; Lu T; Kirchner T; Askari HB; Geisler J; Patch RJ; Gibbs AC; Rady B; Connelly M; Player MR
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4216-22. PubMed ID: 27491708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.
    Wagner S; Scheunemann M; Dipper K; Egerland U; Hoefgen N; Steinbach J; Brust P
    Eur J Med Chem; 2016 Jan; 107():97-108. PubMed ID: 26562545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.
    Zhang Z; Lu X; Xu J; Rothfuss J; Mach RH; Tu Z
    Eur J Med Chem; 2011 Sep; 46(9):3986-95. PubMed ID: 21705115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
    Vlasceanu A; Jessing M; Kilburn JP
    Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.
    Hamaguchi W; Masuda N; Isomura M; Miyamoto S; Kikuchi S; Amano Y; Honbou K; Mihara T; Watanabe T
    Bioorg Med Chem; 2013 Dec; 21(24):7612-23. PubMed ID: 24238902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
    Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
    J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.
    Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
    J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.